Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Shares Shorted: Short Interest Up 1,248.6% in October

Posted by Brian Himes on Nov 10th, 2026

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Free Report) was the recipient of a significant increase in short interest during the month of October. As of October 30th, there was short interest totaling 56,588 shares, an increase of 1,248.6% from the October 15th total of 4,196 shares. Based on an average daily volume of 67,008 shares, the short-interest ratio is presently 0.8 days. Approximately 1.3% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a report on Monday, October 12th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.

Get Our Latest Analysis on Kiora Pharmaceuticals

Institutional Trading of Kiora Pharmaceuticals

A hedge fund recently bought a new position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC acquired a new stake in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 167,941 shares of the company’s stock, valued at approximately $442,000. ADAR1 Capital Management LLC owned approximately 3.80% of Kiora Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Trading Down 8.6%

KPRX stock traded down $0.13 during trading hours on Tuesday, hitting $1.38. 22,770 shares of the stock traded hands, compared to its average volume of 63,740. The stock has a 50-day simple moving average of $2.35 and a 200 day simple moving average of $2.39. Kiora Pharmaceuticals has a one year low of $1.37 and a one year high of $2.91.

Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) last issued its earnings results on Friday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.13.

About Kiora Pharmaceuticals

(Get Free Report)

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.